OZEM vs. PBE ETF Comparison
Comparison of Roundhill GLP-1 & Weight Loss ETF (OZEM) to PowerShares Dynamic Biotech & Genome (PBE)
OZEM
Roundhill GLP-1 & Weight Loss ETF
OZEM Description
OZEM targets the global weight management industry. The fund invests in companies involved in the development of GLP-1 and other weight loss drugs. GLP-1 agonists seek to aid in weight management by lowering blood sugar levels, reducing appetite, and promoting fullness. The portfolio consists of firms with GLP-1 and weight loss drugs that have been approved by or are currently undergoing Phase I, Phase II, and/or Phase III clinical trials of the US Food & Drug Administration (FDA), or any applicable food and drug regulator for non-US companies. The portfolio is constructed using a proprietary methodology, which selects companies with high levels of thematic relevance based on research of each companys public filings and disclosures. In addition, eligible securities must meet minimum market-cap and liquidity requirements. The actively managed fund, although rebalances portfolio weighting on at least a quarterly basis, may have a heavy concentration on a few names.
Grade (RS Rating)
Last Trade
$25.37
Average Daily Volume
38,199
14
PBE
PowerShares Dynamic Biotech & Genome
PBE Description
The PowerShares Dynamic Biotechnology & Genome Portfolio (Fund) is based on the Dynamic Biotech & Genome IntellidexSM Index (Intellidex Index). The Fund will normally invest at least 90% of its total assets in common stocks that comprise the Index. The Intellidex Index is designed to provide capital appreciation by thoroughly evaluating companies based on a variety of investment merit criteria, including price momentum, earnings momentum, quality, management action, and value. The Underlying Intellidex Index is comprised of common stocks of 30 US biotechnology and genome companies. These are companies that are principally engaged in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes and companies that benefit significantly from scientific and technological advances biotechnology and genetic engineering and reseach. The Fund and the Index are rebalanced and reconstituted quarterly in February, May, August and November.Grade (RS Rating)
Last Trade
$68.40
Average Daily Volume
6,342
30
Performance
| Period | OZEM | PBE |
|---|---|---|
| 30 Days | -10.50% | -0.98% |
| 60 Days | -10.19% | -5.20% |
| 90 Days | -10.75% | -4.17% |
| 12 Months | 20.11% |
OZEM Underweight 27 Positions Relative to PBE
| Symbol | Grade | Weight | |
|---|---|---|---|
| UTHR | C | -5.74% | |
| ILMN | C | -5.64% | |
| ALNY | D | -4.78% | |
| BIIB | F | -4.21% | |
| NBIX | C | -4.18% | |
| XNCR | B | -3.88% | |
| EXEL | B | -3.86% | |
| TGTX | B | -3.78% | |
| BMRN | F | -3.76% | |
| MNKD | B | -3.7% | |
| NTRA | A | -3.56% | |
| INCY | C | -3.35% | |
| VCYT | B | -3.28% | |
| ACAD | C | -3.06% | |
| CPRX | C | -3.0% | |
| BPMC | C | -2.91% | |
| TECH | F | -2.89% | |
| VCEL | A | -2.79% | |
| RGEN | D | -2.76% | |
| PTGX | D | -2.75% | |
| QGEN | D | -2.59% | |
| BCRX | D | -2.56% | |
| HALO | F | -2.42% | |
| COLL | F | -2.27% | |
| CDNA | D | -1.92% | |
| NVAX | F | -1.83% | |
| MYGN | F | -1.61% |
OZEM: Top Represented Industries & Keywords
PBE: Top Represented Industries & Keywords
Compare ETFs
